NZ625522B2 - Novel process for the preparation of intermediates of hmg-coa reductase inhibitors - Google Patents
Novel process for the preparation of intermediates of hmg-coa reductase inhibitors Download PDFInfo
- Publication number
- NZ625522B2 NZ625522B2 NZ625522A NZ62552212A NZ625522B2 NZ 625522 B2 NZ625522 B2 NZ 625522B2 NZ 625522 A NZ625522 A NZ 625522A NZ 62552212 A NZ62552212 A NZ 62552212A NZ 625522 B2 NZ625522 B2 NZ 625522B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- formula
- compound
- process according
- hmg
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims abstract description 13
- 239000000543 intermediate Substances 0.000 title abstract description 14
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 title abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 69
- 229960000672 rosuvastatin Drugs 0.000 claims abstract description 10
- BPRHUIZQVSMCRT-VEUZHWNKSA-N Rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims abstract description 9
- VGYFMXBACGZSIL-MCBHFWOFSA-N Pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims abstract description 5
- 229960002797 pitavastatin Drugs 0.000 claims abstract description 5
- 101700038100 estB Proteins 0.000 claims abstract description 3
- -1 amide compound Chemical class 0.000 claims description 40
- 238000006243 chemical reaction Methods 0.000 claims description 39
- 125000006239 protecting group Chemical group 0.000 claims description 22
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 229940088598 Enzyme Drugs 0.000 claims description 17
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 15
- 239000003054 catalyst Substances 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 claims description 11
- 239000004367 Lipase Substances 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 108090001060 lipase Proteins 0.000 claims description 7
- 235000019421 lipase Nutrition 0.000 claims description 7
- 102000004882 lipase Human genes 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 238000005809 transesterification reaction Methods 0.000 claims description 7
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 5
- 229940040461 Lipase Drugs 0.000 claims description 5
- 238000007112 amidation reaction Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000004665 trialkylsilyl group Chemical group 0.000 claims description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N HMG-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims description 3
- 108090000604 Hydrolases Proteins 0.000 claims description 3
- 102000004157 Hydrolases Human genes 0.000 claims description 3
- 229940035295 Ting Drugs 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000002255 enzymatic Effects 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 108091005771 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- KKSAZXGYGLKVSV-UHFFFAOYSA-N butan-1-ol;titanium Chemical compound [Ti].CCCCO KKSAZXGYGLKVSV-UHFFFAOYSA-N 0.000 claims description 2
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 102000033147 ERVK-25 Human genes 0.000 claims 1
- 230000003197 catalytic Effects 0.000 claims 1
- HKJYVRJHDIPMQB-UHFFFAOYSA-N propan-1-olate;titanium(4+) Chemical compound CCCO[Ti](OCCC)(OCCC)OCCC HKJYVRJHDIPMQB-UHFFFAOYSA-N 0.000 claims 1
- 150000005602 pentanoic acid derivatives Chemical class 0.000 abstract description 5
- 108010031797 Candida antarctica lipase B Proteins 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 43
- 239000000203 mixture Substances 0.000 description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 24
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 23
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 239000008346 aqueous phase Substances 0.000 description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 239000010410 layer Substances 0.000 description 14
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 229960001367 tartaric acid Drugs 0.000 description 9
- 239000011975 tartaric acid Substances 0.000 description 9
- 235000002906 tartaric acid Nutrition 0.000 description 9
- 235000019445 benzyl alcohol Nutrition 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 229940011051 isopropyl acetate Drugs 0.000 description 7
- GWYFCOCPABKNJV-UHFFFAOYSA-M isovalerate Chemical compound CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- LMCBEWMQFKWHGU-UHFFFAOYSA-N propan-2-ol;titanium Chemical compound [Ti].CC(C)O LMCBEWMQFKWHGU-UHFFFAOYSA-N 0.000 description 7
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- MSXVEPNJUHWQHW-UHFFFAOYSA-N Tert-Amyl alcohol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
- 235000011114 ammonium hydroxide Nutrition 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- GTFMAONWNTUZEW-UHFFFAOYSA-M glutaramate Chemical compound NC(=O)CCCC([O-])=O GTFMAONWNTUZEW-UHFFFAOYSA-M 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 4
- 229910052719 titanium Inorganic materials 0.000 description 4
- 239000010936 titanium Substances 0.000 description 4
- 101710040797 CAL-B Proteins 0.000 description 3
- SUAFQFDNNCXLIN-QMMMGPOBSA-N CC(C)(C)[Si](C)(C)O[C@@H](CC(N)=O)CC(O)=O Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CC(N)=O)CC(O)=O SUAFQFDNNCXLIN-QMMMGPOBSA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- ZCIAQCXPOPKKQH-JTQLQIEISA-N benzyl (3S)-5-amino-3-hydroxy-5-oxopentanoate Chemical compound NC(=O)C[C@H](O)CC(=O)OCC1=CC=CC=C1 ZCIAQCXPOPKKQH-JTQLQIEISA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000005712 crystallization Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- MMPVRFHOGVTLFR-BYPYZUCNSA-N methyl (3S)-5-amino-3-hydroxy-5-oxopentanoate Chemical compound COC(=O)C[C@@H](O)CC(N)=O MMPVRFHOGVTLFR-BYPYZUCNSA-N 0.000 description 3
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000002194 synthesizing Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N Benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N Benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- VOBDXMJHGGJLRI-HNNXBMFYSA-N CC(C)(C)[Si](C)(C)O[C@@H](CC(N)=O)CC(=O)OCc1ccccc1 Chemical compound CC(C)(C)[Si](C)(C)O[C@@H](CC(N)=O)CC(=O)OCc1ccccc1 VOBDXMJHGGJLRI-HNNXBMFYSA-N 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N Diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 241000982822 Ficus obtusifolia Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960004796 Rosuvastatin calcium Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-M caproate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- YVHPHQBRUPLYOS-UHFFFAOYSA-N dichloromethane;methane Chemical compound C.ClCCl YVHPHQBRUPLYOS-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- 230000001264 neutralization Effects 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- RHGYHLPFVJEAOC-FFNUKLMVSA-L pitavastatin calcium Chemical compound [Ca+2].[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1.[O-]C(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 RHGYHLPFVJEAOC-FFNUKLMVSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective Effects 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N t-BuOH Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- IIJFGHVFGKPJJB-NRFPMOEYSA-N (E,3R,5S)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoic acid;sodium Chemical compound [Na].OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 IIJFGHVFGKPJJB-NRFPMOEYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-M (R)-mandelate Chemical compound [O-]C(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-M 0.000 description 1
- IWYDHOAUDWTVEP-SSDOTTSWSA-N (R)-mandelic acid Chemical compound OC(=O)[C@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-SSDOTTSWSA-N 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-Methylimidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- BHHGXPLMPWCGHP-UHFFFAOYSA-N 2-Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 1
- AKLBQZCEYQQQPR-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O.CCC(C)(C)O AKLBQZCEYQQQPR-UHFFFAOYSA-N 0.000 description 1
- ZQHYXNSQOIDNTL-UHFFFAOYSA-N 3-hydroxyglutaric acid Chemical compound OC(=O)CC(O)CC(O)=O ZQHYXNSQOIDNTL-UHFFFAOYSA-N 0.000 description 1
- RXAJGRHLLRGVSB-UHFFFAOYSA-N 4-[tert-butyl(dimethyl)silyl]oxyoxane-2,6-dione Chemical compound CC(C)(C)[Si](C)(C)OC1CC(=O)OC(=O)C1 RXAJGRHLLRGVSB-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5H-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- ADNGVHHNGMNGBZ-PPHPATTJSA-N C(C)(C)(CC)O.C(C1=CC=CC=C1)OC(C[C@H](CC(=O)N)O)=O Chemical compound C(C)(C)(CC)O.C(C1=CC=CC=C1)OC(C[C@H](CC(=O)N)O)=O ADNGVHHNGMNGBZ-PPHPATTJSA-N 0.000 description 1
- CTZDWHZODOCMCT-SECBINFHSA-M COC(=O)C[C@@H](CC([O-])=O)O[Si](C)(C)C(C)(C)C Chemical compound COC(=O)C[C@@H](CC([O-])=O)O[Si](C)(C)C(C)(C)C CTZDWHZODOCMCT-SECBINFHSA-M 0.000 description 1
- 229940066901 Crestor Drugs 0.000 description 1
- GQHTUMJGOHRCHB-UHFFFAOYSA-N DBU Substances C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N Glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- DFOMSPXAQXAMAN-QMMMGPOBSA-N O([Si](C)(C)C(C)(C)C)[C@H](C(=O)O)CCC(=O)O Chemical compound O([Si](C)(C)C(C)(C)C)[C@H](C(=O)O)CCC(=O)O DFOMSPXAQXAMAN-QMMMGPOBSA-N 0.000 description 1
- YEQXTNAAHMATGV-UHFFFAOYSA-M OC(C(=O)[O-])CCC(=O)N Chemical compound OC(C(=O)[O-])CCC(=O)N YEQXTNAAHMATGV-UHFFFAOYSA-M 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 102000035443 Peptidases Human genes 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- GETTZEONDQJALK-UHFFFAOYSA-N Trifluorotoluene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 1
- OHXRQTWUHFMFCZ-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OC(C(=O)N)CCC(=O)O Chemical compound [Si](C)(C)(C(C)(C)C)OC(C(=O)N)CCC(=O)O OHXRQTWUHFMFCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- ZXDVQYBUEVYUCG-UHFFFAOYSA-N dibutyltin(2+);methanolate Chemical compound CCCC[Sn](OC)(OC)CCCC ZXDVQYBUEVYUCG-UHFFFAOYSA-N 0.000 description 1
- OUWSNHWQZPEFEX-UHFFFAOYSA-N diethyl glutarate Chemical compound CCOC(=O)CCCC(=O)OCC OUWSNHWQZPEFEX-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- CUPGMRSSZADEIW-UHFFFAOYSA-N dimethyl 3-hydroxypentanedioate Chemical class COC(=O)CC(O)CC(=O)OC CUPGMRSSZADEIW-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- XGZNHFPFJRZBBT-UHFFFAOYSA-N ethanol;titanium Chemical compound [Ti].CCO.CCO.CCO.CCO XGZNHFPFJRZBBT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- GTFMAONWNTUZEW-UHFFFAOYSA-N glutaramic acid Chemical compound NC(=O)CCCC(O)=O GTFMAONWNTUZEW-UHFFFAOYSA-N 0.000 description 1
- YURNCBVQZBJDAJ-UHFFFAOYSA-M hept-2-enoate Chemical group CCCCC=CC([O-])=O YURNCBVQZBJDAJ-UHFFFAOYSA-M 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 229960003296 pitavastatin calcium Drugs 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 150000003336 secondary aromatic amines Chemical class 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 108010079522 solysime Proteins 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000003510 tertiary aliphatic amines Chemical class 0.000 description 1
- 150000003513 tertiary aromatic amines Chemical class 0.000 description 1
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium(IV) ethoxide Substances [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 229940086542 triethylamine Drugs 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/02—Amides, e.g. chloramphenicol or polyamides; Imides or polyimides; Urethanes, i.e. compounds comprising N-C=O structural element or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
- C12P17/12—Nitrogen as only ring hetero atom containing a six-membered hetero ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/42—Hydroxy-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
- C12P7/44—Polycarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Provided is a process for the preparation of chiral pentanoic acid derivative intermediates of the general formula II, which are useful in the preparation of HMG-CoA reductase inhibitors such as rosuvastatin or pitavastatin. The initial step of the process involves the use of the enzyme Candida antarctica lipase B. Further provided are intermediate compounds and their preparation. rctica lipase B. Further provided are intermediate compounds and their preparation.
Description
NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-COA
REDUCTASE TORS
AH26(10927034_1):LNB
WO 80219
H3C.N
o=$=o CH3
Formula-A
Rosuvastatin calcium is marketed under the etary name CRESTOR for treatment of
mammals such as human and administrated as daily dosage form of 5 mg, 10 mg, 20 mg
and 40 mg.
Rosuvastatin and its pharmaceutically able salts were first disclosed in European
patent publication EP 0521471. It also discloses process for the preparation of
Rosuvastatin calcium.
Bis{(3R, SS, 6E)[2-cyclopropyl(4-fluorophenyl)—3-quinolyl]-3,5-dihydroxy-
6-heptenoate} menocalcium of Formula-B (Pitavastatin .Calcium) is an HMG-CoA
reductase inhibitor, developed by Nissan Chemical Industries for the ent of
hyperlipidemia.
l 5 a-B
Pitavastatin and its pharmaceutically acceptable salts were first disclosed in European
patent publication EP 0304063. It also discloses process for the preparation of
Pitavastatin sodium.
United States Patent No. 5,260,440 and PCT publication No. WO 03/097614, disclose the
synthesis of Rosuvastatin from the intermediate 3(R)-3(tert—butyldimethylsilyloxy)
oxotriphenyl-phosphoranylidene hexanoate.
PCT publication No. W0 112 discloses the synthesis of Rosuvastatin from
intermediate, -(t-butyldimethylsilyloxy)dimethoxyphosphinylox0-hexanoate.
US 5,117,039 discloses the process for the ation of (3R)[(tert-
butyldimethylsilyl) oxy] pentanedioic acid, 1-[(R)-Mandelic acid] Ester by the ring
opening of 3-[(tert-Butyldimethylsilyl)oxy] pentanedioic anhydride using benzyl D-
mandelate which gives less yields along with impurities.
US 20090076292 discloses process for the preparation of Rosuvastatin by using the
intermediates 3(R)-3(tert-butyldimethylsilyloxy)oxotriphenyl-phosphoranylidene
ate and (3R)(t-butyldimethylsilyloxy)dimethoxyphosphinyl-S-oxo-
hexanoate. These intermediates are prepared by a novel intermediate i.e. chiral base salt
of hydroxy protected diethyl glutarate.
US 2005/0070605 A1 discloses the oselective opening of 3-hydroxy protected
ic anhydride by phenylethylamine to form an amide bond, and further conversion to
obtain the HMG-CoA ase inhibitor.
The compound 3(R)—3(tert-butyldimethylsilyloxy)oxotriphenyl-phosphoranylidene
hexanoate can be prepared from the pentanoic acid derivatives of the following Formula-
II.
0 OX 0
Formula-II
wherein X is hydrogen or hydroxy protecting group and R1 is carboxyl protecting group.
In prior art nd of Formula-II is prepared by the resolution of the racemate or
asymmetric synthesis. These routes have disadvantages in the industrial scale preparation.
The present invention provides an industrially scalable process for the pentanoic acid
derivatives of Formula—II and further conversion to HMG-CoA reductase inhibitors.
OBJECT AND SUMMARY OF THE INVENTION:
The principle object of the present invention is to provide novel process for the
preparation of pentanoic acid derivatives of Formula-11‘ and further conversion into
HMG-CoA ase inhibitors.
0 ox o
HOWOR,
‘ I
Formula-II
wherein X is hydrogen or hydroxy protecting group and R1 is carboxyl ting group.
One aspect of the present invention provides, s for the preparation of compound of
Formula-II comprising the steps of:
a) enzymatic enantioselective amidation of nd of a-III in presence of
suitable enzyme to get amide compound of Formula-IV
0 OH 0 0 OH O
MOWOR R2O NH
2 2
Formula—III Formula-IV
n R2 is C1-C5 alkyl or aryl or arylalkyl group;
b) transesterification of compound of Formula-IV into compound of Formula-V
O OH O
RSOWNHZ
Formula-V
wherein Ryis C1-C5 alkyl or aryl or arylalkyl group with proviso that R3 is
ent than the R2 of Formula-IV;
c) protecting the hydroxy group with suitable hydroxy protecting group to get
compound of Formula-VI
0 OX 0
RsOWNHZ
Formula-VI
wherein X is suitable protecting group;
d) converting the compound of a-VI into compOund of Formula-VII; and
0 OX 0
HOWNH2
Formula-VII
e) converting compound of Formula-VII into compound of Formula-II.
0 OX 0
HOW0R1
Formula-II
wherein R1 is carboxyl protecting group and X is defined above.
DETAILED DESCRIPTION OF THE INVENTION:
The present invention s to novel process for the preparation of pentanoic acid
derivatives of compound of Formula-II, used as intermediates of HMG—CoA reductase
inhibitors and further conversion to HMG-CoA reductase inhibitors.
The compound of Formula-II is used in the ation of heptenoate side chain
intermediates ofHMG-CoA reductase tors.
One aspect of the present invention provides process for the ation of compound of
Formula-II comprising the steps of:
a) tic enantioselective amidation of compound of Formula-III in ce of
suitable enzyme to get amide compound of Formula-IV
0 OH O ‘
R20 0R2 R20 NHZ
Fonnula—III Formula-IV
wherein R2 is C1-C5 alkyl or aryl or arylalkyl group;
b) transesterification of compound of Formula-IV into compound of Formula-V
O OH O
1.on
Formula-V
n R3 is, C1-C5 alkyl or aryl or arylalkyl group with o that R3 is
different than R2 of Formula-IV;
c) protecting the hydroxy group with suitable hydroxy protecting group to get
compound of Formula-VI
0 OX 0
R3OWNHZ
Formula-VI
wherein X is a le ting group;
d) converting the compound of Formula-VI into compound of a-VII; and
o ox o
Formula-VII
e) converting compound of Formula-VII into compound of Formula-II
0 OX 0
HOWORI
Formula-II
wherein R1 is carboxyl protecting group and X is defined above.
R1 of the present invention is selected from carboxyl protecting group and X is hydroxy
protecting group. Suitable protecting groups are available in the literature and well
familiar to the person skilled in the art. Examples of le protecting groups can be
found in standard works, such as J. F. W. McOmie, "Protective Groups in Organic
Chemistry", Plenum Press, London and New York 1973, in T. W. Greene and P. G. M.
Wuts, "Protective Groups in Organic Synthesis", Third edition, Wiley, New York 1999,
in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer), Academic Press,
London and New York 1981 in "Methoden der organischen Chemie", Houben-Weyl, 4th
n, Vol. 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H.
Jescheit, "Aminosauren, e, Proteine", Verlag Chemie, Weinheim, Deerfield Beach,
and Basel 1982, and or in Jochen Lehmann, "Chemie der Kohlenhydrate:
Monosaccharide und Derivate", Georg Thieme Verlag, Stuttgart 1974. Preferable
carboxyl protecting groups are C1-C5 alkyl, aryl, arylalkyl, more preferably C1—C5 alkyl.
Suitable hydroxy protecting groups are alkyl, aryl, arylalkyl, trialkylsilyl and
diarylalkylslyl. Preferably trialkylsilyl or diarylalkylslyl. The protecting groups are
trimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl or diphenyl(tert—butyl)silyl
group.
As per the present invention, in step-a, compound of formula III is selectively amidified
by using enzyme. The enzyme used in this reaction is selected from hydrolytic enzymes,
e.g. lipases, esterases, proteases. The preferred enzymes are microbial lipases that show
amidation activity of esters with ammonia or amines in c media. Exceptional
performance is ed by using lipases from the Candida genus, especially the Candida
antartica lipase. The isoenzyme B is most red. To obtain acceptable activity for
hydrolases in organic media, immobilization of the enzyme on a porous solid t is
advantageous. The suitable enzyme used is an immobilized version of Candida antartica
lipase B using anhydrous ammonia in an organic solvent. The organic solvent used in this
step is an alcohol solvent or ethereal solvent. The alcohol t is ed from
ethanol, methanol, isopropanol, tert-butanol or 2—methylbutan-2—ol (tert—Pentanol), 2-
methyl-Z-butanol, preferably tert-Pentanol. The ethereal solvent is selected from
tetrahydrofuran, diethyl ether, methyl tert-butyl ether ,2-methyltetrahydrofuran,
cyclopentyl methyl ether, 1,4-dioxane, dimethoxyethane, diethyleneglycol diemthyl
ether, preferably 1,4-dioxane. The obtained monoamide ester intermediate compound of
Formula-IV is tallized to highly enantiomeric compound of Formula-IV.
The step-b of this ion involves transesterification of compound of Formula-IV. The
transesterification of the nd of Formula-IV is d out in presence of catalyst.
The suitable catalyst is selected from sts, which shows high sterification
ty under essentially neutral ions, as the compounds of formula IV and
a V show limited optical stability under the usual strongly basic transesterification
conditions. Catalysts that are active under essentially neutral conditions are
dialkyltindialkoxide (e.g. dibutyltin dimethoxide) and tetraalkyl esters of titanium, e.g.
tetramethyl orthotitanate, tetraethyl orthotitanate, tetrapropyl itanate, tetraisopropyl
orthotitanate, tetrabutyl orthotitanate and tetrabenzyl itanate. Most preferred is the
cially available tetraisopropyl orthotitanate. In a l embodiment the
tetraisopropyl orthotitanate can be first mixed with excess benzyl alcohol under vacuum
to produce a on of tetrabenzyl itanate in benzyl alcohol. In this reaction very
less amount of catalyst is used. The compound of Formula-IV is reacted with respective
alcohol compound to yield required ester. In this reaction preferably araylalkyl ester,
more preferably benzyl ester is ed by reacting compound of Formula-IV with
benzyl alcohol. The preferable catalyst used in this reaction is titanium catalyst and the
titanium catalyst needs to be removed from the product. In most procedures this involves
on of some water to form insoluble hydrated TiOz, but this generates a precipitate
with unfavorable filtration propertiesuAn alternative workup process has been ped,
in which the reaction mixture is added to an aqueous solution of (DL/meso) tartaric acid:
The tartaric acid forms a water soluble and stable titanium x, while releasing the
benzyl amidoester to the organic phase.
The step-c of this invention involves protection of the compound of Formula-V. The
compound of Formula-V is protected by suitable protecting group such as alkyl, aryl,
arylalkyl, trialkylsilyl and diarylalkylslyl in presence of base and organic solvent. The
suitable protecting group used in this reaction is tert-Butyldimethylsilyl group. The base
is selected from tertiary aliphatic amines or secondary aromatic or tertiary aromatic
amines such as triethyl amine, diisopropylethylamine, N-methyl morpholine, pyridine, 4-
dimethylaminopyridine, DBU, DBN, imidazole and N—methylimidazole, preferably
imidazole. The organic solvent used in this reaction is a polar aprotic solvent, such as
dichloromethane, chloroform, 1,2—dichloroethane, trifluoromethylbenzene,
dimethylformamide, ylacetamide, N-methylpyrrolidone, dimethylsulfoxide,
sulfolane, acetonitrile, benzonitrile, preferably dimethylformamide.
The step-d of this invention involves conversion of compound of Formula-VI to
compound of Formula-VII. This sion can be carried out by hydrolysis or catalytic
hydrogenation of compound Vof Formula-VI. The catalytic hydrogenation of compound of
Formula-VI is takes place in the presence of catalyst selected from transition metals that
show hydrogenolysis of benzyl ester, preferably palladium on d support like Pd/C or
Pd/A1203, preferably Pd catalyst in presence of hydrogen in an ester, l, ether or
ic solvents, ably ester t. The preferable ester solvent is ethyl acetate.
The step-e of this invention involves the conversion of compound of Formula-VII into
nd of Formula-II by the conversion of the amide to 'an ester. The reaction
involves usage of ylformamide dimethylacetal under mild basic conditions. Under
mild basic conditions this reagent converts the amide to a reactive acylformamidine,
which then reacts with alcohols to form the corresponding ester, while it suppresses the
esterification of the free carboxylic acid group. The base used in this, reactionis selected
from alkalimetal alkoxides like sodium methoxide or ium methoxide, preferably
sodium methoxide. The solvent used in this reaction is methanol.
Advantages of the present invention
The current reaction scheme avoids the use of chiral auxiliaries, cryogenic reaction
conditions and yields an overall higher yield of desired optically pure monoester of
formula II. The low amount of enzyme used in the first step can be recycled and reused
many times, thus ing the tion cost of the desired product. Many of the
intermediates are crystalline solids that can be upgraded in chemical and optical purity by
crystallization.
The compound of Formula-III is prepared by the prior art process as disclosed in
Tetrahedron;43(1);45-58;1987, Canadian journal of chemistry;66(6);1422-4;1988 and
Journal of the American chemical society;68;721 ; 1946.
The compound of Formula-II is further converted into HMG-CoA reductase inhibitors of
Formula-I by the conventional methods as disclosed in US RE 37,314, US 440,
WO 2003087112, US 2007037979 and CN 100506796.
For example the compound of a-II is further ted into Rosuvastatin m
by the following procedure as depicted in the below scheme.
0 OX 0 Th C ox o
HOWORII ————> Ph—P/\
Ph I
Formula-II
N \ \o
H3CNAN’I CH3
o=s=o CH3
Deprotection
<———-
Reduction
0H 0
0‘R Hydrolysis
NI . . ____.__> Rosuvastatin m
H3C.N/I\N’ CH3 Salt formation
O=§=O CH3
For example the compound of Formula-II is further converted into Pitavastatin calcium
by the following procedure as depicted in the below scheme.
0 OX o If“ 0 OX 0
' W Ph_P\
HO 0Rl / 0R1
Formula-II
Deprotection
‘—-——-
Reduction
Hydrolysis
ORl ———> Pitavastatin Calcium‘
Salt formation
All s, patent ations, and non-patent publications cited herein by reference
should be considered in their entirety. The invention is illustrated with the following
examples, which are provided by way of illustration only and should not be construed to
limit the scope of the invention.
2012/000770
Experimental procedure:
Example —- 1: Process for the Preparation of compound of Formula-IV (where
R2=Me)
Tert—Pentanol (1.1 L). was saturated with gaseous a until about 1 mo] (17 g) has
been evaporated from the ammonia cylinder. To this Compound of Formula-Ill (R2=Me)
(125 g; 0.7lmol) was added, followed by the addition of immobilized CAL-B -
T 1-350; 12.5 g). The reactor was closed and mechanically stirred at ambient temperature.
After completion of the reaction enzyme was removed by filtration over a 100 um sieve
and washed with methanol. The filtrate evaporated under reduced pressure at a
temperature below 50 °C_ to yield an oily residue. This residue was purified by
crystallization from pyl acetate to yield (S)-Methyl 3-hydroxyglutaramate.
Example — 2: Process for the Preparation of compound of Formula-V (where
R3=Benzyl) ‘
(S)—Methyl 3-hydroxyglutaramate ed from e-1 (16.1 g; 0.1mol) was mixed
with benzyl alcohol (25 g). The e was heated under vacuum (< 15 mbar) at 55 °C
to remove traces of moisture. Neat tetraisopropyl orthotitanate (3 ml; 10mol %) was
added and the mixture heated under full vacuum for 3h at 55-57 °C. The mixture was
cooled and diluted with 1 volume of Tetrahydrofuran. The organic mixture was slowly
added in 10m to a vigorously stirred e of aqueous tartaric acid (1 M, 100 ml) and
ethyl acetate. The organic phase was d and the aqueous phase extracted with ethyl
acetate. The combined organic extracts were washed with dilute sodium bicarbonate
solution. The organic phase was evaporated under reduced pressure and MTBE was
added and the mixture cooled with stirring. The obtained thick suspension was filtered
and washed with cold MTBE and pentane to yield (S)—Benzyl 3-hydroxyglutaramate.
— 3:
. Example Process for the ation of compound of Formula-VI (where
zyl and X= Tert-butyldimethylsilyl)
'30 A mixture of (S)-Benzyl 3-hydroxyglutaramate (66 g; 0.28 mol; 97 % e.e.) and imidazole
(23 g; 0.34 mol; 1.2 eq.) was mixed with dimethylformamide‘ (70 ml). To this mixture a
solution of tert-Butyldimethylsilyl de (45 g; 0.3 mol) in dimethylformamide (150
ml) was added under cooling (+5 °C). The mixture was warmed to 25 °C and stirred for
lhour. The mixture was quenched with water. The mixture was diluted further with water
and extracted with isopropylacetate. The organic extract was washed with water and
diluted with sodium onate and brine. ‘ After evaporation (S)-Benzyl 3-[tert-
butyldimethylsilyloxy]glutaramate as an oil was obtained.
Example — 4: s for the Preparation of compound of Formula-VII (where X=
Tert-butyldimethylsilyl)
(S)-Benzyl 3-[tert-butyldimethylsilyloxy]glutaramate from example-3 (48.5 g) was
dissolved in ethyl acetate (350 ml) and placed in a 500 ml glass pressure reactor with
magnetic stirring. Palladium on charcoal catalyst (5 %, 0.48 g) was added to this and the
mixture was enated under 2.7 atmosphere of hydrogen for 4 hours. The pressure
was released and the e was d. The catalyst was washed with 25' ml ethyl
acetate and kept for reuse. The” filtrate was mixed with'water. The pH of the mixture was
adjusted to 8.5 using 2.5 M aqueous ammonia under stirring. The aqueous phase was
extracted once with MTBE. The clear aqueous phase was cooled to + 5 °C and slowly
acidified to pH 4.4 using conc HCl. A thick itate was formed at pH 4.8-5. The
mixture was filtered and the solid was washed once with Water and dried under reduced
pressure to yield (S)[tert-butyldimethylsilyloxy]glutaric acid monoamide.
Example — 5: Process for the Preparation of compound of Formula-II (where X=
Tert-butyldimethylsilyl and R1=Me)
(S)[tert-Butyldimethylsilyloxy]glutaric acid monoamide (4.6 g) was dissolved under
argon atmosphere in anhydrous methanol (30 ml). The pH of the reaction mixture was
adjusted to 11.4 by the addition of sodium methoxide solution (3.6 ml 30 %). The
on was mixed under argon with 5.0 g of dimethylformamide dimethylacetal (42
mmol). The mixture was stirred under inert atmosphere for 20h at 30 °C. The obtained
mixture was slowly added to a stirred e of dichloromethane and dilutes phosphoric
acid. The organic phase was washed with water and evaporated to give (R)-Methyl 3-
[tert-butyldimethylsilyloxy]glutarate.
WO 80219 2012/000770
Example — 6: Process for the Preparation of (S)-methylhydroxyglutaramate
Tert-pentanol (800 ml) was saturated With ammOnia gas to about 1.0-1.5'mole. To this
dimethy1hydroxy glutarate (100 g) was added followed by the addition of 3 g
immobilized CAL-B(CAL B-Tl-AMDZ). The flask was closed and stirred at 20-25°C.
After completiOn of reaction enzyme was removed by filtration and washed the enzyme
with tert-pentanol (100 ml). The filtrate was evaporated under reduced pressure 'at a
ature below 50°C to yield a residue. This e was purified by crystallization
from tertrpentanol/tert-butyl methyl ether mixture to give (S)—methy1
hydroxyglutaramate.
Example — 7: Process for the Preparation of (S)-Benzylhydroxyglutaramate
Mixture of Benzyl alcohol (131.0 g), (S)-methy1—3-hydroxyglutaramate (100 g) and
Tetraisopropyl orthotitanate (17.5 g) are mixed in a flask. The mixture was stirred under
vacuum at 50-60°C for about 5 hrs. The reaction mixture was cooled and diluted with
isopropyl e (500 ml). The on mixture was added to a stirred on of
Tartaric acid (37 g in 370 ml DM water) and 500 ml isopropyl acetate mixture. The
on mixture was stirred and pH was adjusted to 0 by Aq ammonia solution.
Layers were separated. The organic phase was removed and the aqueous phase was
ted with isopropyl acetate. Combined organic layer was Washed with Aq ammonia
and tartaric acid solution followed by brine wash. The organic phase Was dried over
anhydrous sodium sulphate and evaporated under reduced pressure to yield oil. To this oil
utyl methyl ether (800 ml) was added, stirred, cooled, filtered and dried to give (S)-
Benzylhydroxyglutaramate.
Example — 8: Process for the Preparation of (S)-Benzylhydroxyglutaramate
Mixture of Benzyl alcohol (131.0 g), (S)-methy1hydroxyglutaramate .(100 g) and
Tetraisopropyl orthotitanate (17.5 g) are mixed in a flask. The mixture was stirred under
vacuum at C for about 5 hrs. The reaction mixture was cooled and diluted with
dichloromethane (500 ml). The reaction mixture was added to a stirred solution of
Tartaric acid (37 g in 370 ml DM water) and 500 ml dichloromethane mixture. The
reaction mixture was stirred and pH was adjusted to 7.0-8.0 by Aq ammonia solution.
Layers were separated. The organic phase was removed and the aqueous phase was
extracted with dichloromethane. Combined organic layer was washed with Aq a
and tartaric acid solution followed by brine wash. The organic phase was dried over
anhydrous sodium sulphate and evaporated under reduced pressure to yield oil. To this oil
tert-butyl methyl ether (800 ml) was added, stirred, cooled, filtered and dried to give (S)-
‘ Benzylhydroxyglutaramate.
Example — 9: Process for the Preparation of (S)-benzyl(tert-butyl
ylsilyloxy) amate
(S)-Benzylhydroxyglutaramate (100 g) was dissolved in dimethyl formamide. To this
Imidazole (35 g) was added and the solution was cooled to 5°C. To this a solution of tert-
butyldimethylsilylchloride (68.5 g) dissolved in yl formamide (250 ml) was added
under cooling. The e was warmed to 20-25°C and stirred. The reaction mixture
was cooled and ed with water. To the reaction mixture ethyl acetate and water was
added and stirred. The layers were separated and the organic phase was washed thrice
with water. The organic phase was evaporated under reduced re to yield (S)-
benzyl(tert-butyl dimethylsilyloxy) glutaramate as oil.
Example — 10: s for the Preparation of (S)(tert-butyl dimethylsilyloxy)
glutaric acid monoamide
(S)-Benzyl(tert-butyl dimethylsilyloxy) amate (100 g) was dissolved in ethyl
acetate and placed in pressure flask. To this Palladium on charcoal (5 %, 1 g) was added
and stirred under hydrogen atmosphere (~ 2.8 Kg). Palladium was removed by filtration.
‘ The filtrate was mixed with water and adjusted pH to ~ 9.0 by using Aq ammonia
solution. The reaction mass was stirred and layers were separated. The aqueous phase
was washed with romethane and dichloromethane was added to aqueous phase.
The reaction mass was cooled to 5°C and pH was adjusted to 4.0 with Aq phosphoric
acid. The reaction mass was stirred and layers were separated. The organic phase was
washed with water and dried over sodium sulphate. The organic layer was evaporated
under vacuum to yield residue. Residue was dissolved in dichloromethane and to this
solution heptane was added, stirred, d and dried to yield (tert-butyl
dimethylsilyloxy) glutaric acid monoamide.
Example -— 11: Process for the ation of ($)(tert—butyl dimethylsilyloxy)
glutaric acid monoamide
(S)-Benzyl-3—(tert-butyl dimethylsilyloxy) glutaramate (100 g) was dissolved in ethyl
acetate and placed in pressure flask. To this ium on charcoal (5 %, 1 g) was added
and d under hydrogen atmosphere (~ 2.8 Kg). ium was removed by filtration.
The filtrate was mixed with water and adjusted pH to ~ 9.0 by using Aq ammonia
solution. The reaction mass was stirred and layers were separated. The aqueous phase
was washed with dichloromethane and romethane was added to aqueous phase.
The reactiOn mass was cooled to 5°C and pH was adjusted to 4.0 with Aq phosphoric
acid. The reaction mass was stirred and layers were separated. The organic phase was
washed with water and dried over sodium sulphate. The organic layer was evaporated
under vacuum to yield residue. Residue was dissolved in dichloromethane and to this
solution pentane was added, stirred, filtered and dried to yield (S)(tert-butyl
dimethylsilyloxy) glutaric acid monoamide.
Example — 12: Process for the Preparation of (S)(tert-butyl dimethylsilyloxy)
glutaric acid monoamide
(S)-Benzyl—3-(tert-butyl dimethylsilyloxy) glutaramate (100 g) was dissolved in ethyl
acetate and placed in pressure flask. To this Palladium on charcoal (5 %, l g) was added
and d under hydrogen atmosphere (~ 2.8 Kg). ium was removed by filtration.
The filtrate was mixed with water and adjusted pH to ~ 9.0 by using Aq ammonia
on. The reaction mass was stirred and layers were separated. The aqueous phase
was washed with dichloromethane and dichloromethane was added to aqueous phase.
The reaction mass was cooled to 5°C and pH was adjusted to 4.0 with Aq phosphoric
acid. The reaction mass was stirred and layers were separated. The organic phase was
washed with water and dried over sodium sulphate. The organic layer was evaporated
under vacuum to yield residue. Residue was dissolved in dichloromethane and to this
solution hexane was added, stirred, filtered and dried to yield (S)(tert-butyl
dimethylsilyloxy) ic acid monoamide.
Example - 13: s for the Preparation of (R)—Methy1—3-(tert-
butyldimethylsilyloxy)glutarate
(S)—3-(tert-butyl dimethylsilyloxy) glutaric acid monoamide (100 g) was dissolved in
methanol (650 ml) under nitrogen here. The reaction mass was ~ 25 % Sodium
methoxide solution (82.9 g) was added under cooling. Then reaction mass was heated to
~ 25°C and to this dimethyl formamide dimethylacetal (100 g) was slowly added. The
'10 e was stirred for ~ 20 hrs at 25°C. The reaction mass was slowly added to a stirred '
mixture of dichloromethane and diluted phosphoric acid solution. Layers were separated.
The organic phase was washed thrice with water, dried over sodium sulphate and
evaporated under d pressure to yield (R) —Methyl(tert-butyldimethylsilyloxy)
glutarate.
Example — 14: Process for the Preparation of (S)-Benzyl-3—hydroxyglutaramate
Tert-pentanol (800 ml) was saturated with ammonia gas to about 1.0-1.5 mole. To this
dimethyl—3-hydroxy glutarate (100 g) was added followed by the addition of 3 g
immobilized CAL-B (CAL B-Tl-AMDZ). The flask was closed and stirred at 20-25°C.
Afier completion of reaction enzyme was removed by filtration and washed the enzyme
with tert-pentanol (100 ml). The filtrate was evaporated under reduced re at a
temperature below 50°C to yield a residue. To this residue mixture of Benzyl alcohol
(131.0 g), (S)-methyl—3-hydroxyglutaramate (100 g) and Tetraisopropyl orthotitanate
(17.5 g) are mixed in a flask. The mixture was stirred under vacuum at 50-60°C for about
5 hrs. The reaction mixture was cooled and diluted with isopropyl acetate (500 ml). The
reaction mixture was added to a stirred solution of Tartaric acid (37 g in 370 ml DM
water) and 500 ml isopropyl acetate mixture. The reaction mixture was stirred and pH
was adjusted to 7.0-8.0 by Aq ammonia solution. Layers were separated. The organic
phase was removed and the aqueous phase was extracted with pyl acetate.
Combined organic layer was washed with Aq ammonia and tartaric acid solution
ed by brine wash. The organic phase was dried over ous sodium sulphate
and evaporated under reduced re to yield oil. To this oil tert-butyl methyl ether
(800 ml) was added, stirred, cooled, filtered and dried to give (S)-Benzyl—3-
hydroxyglutaramate.
Example —- 15: Process for the Preparation of (S)(tert-butyl dimethylsilyloxy)
glutaric acid ide
(S)-Benzylhydroxyglutaramate (100 g) was dissolved in dimethyl formamide. To this
ole (35 g) was added and the solution was cooled to 5°C. To this a solution of tert-
butyldimethylsilylchloride (68.5 g) dissolved in yl formamide (250 ml) was added
under cooling. The mixture was warmed to 20-25°C and stirred. The reaction mixture
was cooled and quenched with water. To the reaction mixture ethyl acetate and water was
added and stirred. The layers were separated and the organic phase was washed thrice
with water. Tothe c phase Palladium on al (5 %, 1 g) was added and stirred
under hydrogen atmosphere (~ 2.8 Kg). Palladium was removed by filtration. The filtrate
was mixed with water and adjusted pH to ~ 9.0 by using Aq a solution. The
reaction mass was stirred and layers were separated. The aqueous phase was washed with
dichloromethane and dichloromethane was added to aqueous phase. The reaction mass
was cooled to 5°C and pH was adjusted to 4.0 with Aq phosphoric acid. The reaction
mass was stirred and layers were separated. The organic phase was washed with water
and dried over sodium sulphate. The organic layer was evaporated under vacuum to yield
residue. Residue was dissolved in dichloromethane and to this solution heptane was
added, stirred, filtered and dried to yield (S)(tert-butyl dimethylsilyloxy) glutaric acid
monoamide.
Example — 16: Process for the Preparation of (S)-methylhydroxyglutaramate
Tert-pentanol (200 ml) was saturated with anhydrous ammonia at ambient pressure. This
was cooled to ambient temperature and to this CaLB-Tl-AIVfl) enzyme (1.25 g) and
yl 3-hydroxyglutarate (25.3 g) were added. The resulting mixture was gently
stirred with a magnetic stirrer at ambient temperature (20-21 °C) for 18h. The enzyme
was removed by filtration and washed with tert—pentanol (25 ml). The clear e (200
g) was concentrated under reduced re at a maximum temperature of + 50 °C to
light brown oil. The oil was again dissolved in tert-pentanol (90 ml) and placed in a
ically stirred 500 ml vessel. To this MTBE (Methyl tert-butyl ether) was slowly
added under seeding with methyl (S)hydroxyglutaramate (10 mg). The crystal
suspension was cooled in an ice—bath to +5 °C. The reaction mass was filtered, washed
with MTBE and dried to yield (S)§methylhydroxyglutaramate.
Example — 17: Process for the Preparation of (S)-Benzylhydroxyglutaramate
(S)-Methyl-3—hydroxyglutaramate (41.2 g) and benzyl alcohol (54 g) were placed in a
250 ml flask. This mixture 'was heated under vacuum to 55 °C to get clear solution. To
this neat soprOpyl orthotitanate (7.5 ml) was added. The mixture was d at 55-
58 °C under vacuum. The reaction mixture was diluted with isopropyl acetate and added
to a solution of tartaric acid (7.5 g in 50 ml water) and isopropyl acetate (200 ml). The
organic phase was removed and washed with water, NaHC03-solution and brine. The
organic phase was dried over sodium sulfate and evaporated to blue oil. The aqueous
phases were additionally extracted with ethyl acetate to yield colorless oil. The combined
oily al was mechanically stirred with MTBE and seeded with (S)—Benzyl
hydroxyglutaramate. The thick suspension was cooled in an ice-bath to 5 °C and aged for
15m, ed by filtration. The solid was washed with MTBE and pentane (50 ml). The
resulting was dried to yield (S)-Benzylhydroxyglutaramate.
Example —— 18: Process for the Preparation of (S)-benzyl(tert-butyl
ylsilyloxy) glutaramate
(S)-Benzylhydroxyglutaramate (49.5 g) was dissolved in anhydrous
dimethylformamide (50 ml) and added to a 500 ml flask containing solid imidazole (17.1
g). To this a solution of tert—butyldimethylsilyl chloride (34 g) in dimethylformamide
(120 ml) was added and reaction flask was cooled in an th. The reaction was
quenched by addition of saturated ethyl acetate. The mixture was stirred at ambient
temperature. To this water was added and the biphasic mixture was stirred for 1 hour.
The mixture wasthen washed with water. The organic phases were mixed and washed
with water to remove traces of dimethylformamide. The c phase was ated
under reduced pressure to yield (S)—benzyl(tert-butyl dimethylsilyloxy) glutaramate.
Example — 19: Process for the Preparation of (S)—3-(tert-butyl dimethylsilyloxy)
glutaric acid monoamide
(S)-benzyl—3-(tert-butyl dimethylsilyloxy) glutaramate (70 g) was dissolved in ethyl
acetate (350 ml) and placed in a 500 ml glass pressure vessel. To this dry 5% Pd/C (1.4 g)
was added under vacuum and pressurized with hydrogen gas at 2.7 bar overpressure. The
mixture was stirred magnetically while remaining connected to the en source. The
catalyst was removed by filtration and washed with a small volume of ethyl acetate (25
ml). The clear filtrate was mixed with water and dilute ammonia. The aqueous phase was
isolated and the organic phase extracted with water. The ed aqueous phase was
washed with MTBE and degassed under vacuum to remove traces of organic solvent. The
mixture was placed in an ice-bath. The cooled aqueous on was acidified using dilute
phosphoric acid to obtain thick suspension. This was filtered, washed with cold water and
dried to yield (S)—3-(tert-butyl dimethylsilyloxy) glutaric acid monoamide.
Example — 20: Process for the Preparation of (R)—Methyl(tertbutyldimethylsilyloxy
rate
(S)(tert-butyl dimethylsilyloxy) glutaric acid monoamide (10 g) was ved in
anhydrous methanol (90ml) and placed under Argon. To this mixture sodium methoxide
solution (8.6 g) was added. To this neat dimethylformamide dimethyl acetal (10 g) was
added and the resulting mixture stirred under Argon at 30 °C for 16 hours. The mixture
was cooled and added to a pre cooled mixture of ethyl acetate (150 m1) and aqueous citric
acid (19 g in 100 ml water). To the ing homogeneous mixture MTBE and brine was
added. The organic phase was washed twice with water and dried using a brine wash and
sodium sulfate. The dried on was carefully evaporated to yield (R)—Methyl(tert-
butyldimethylsilyloxy)glutarate.
WE
Claims (24)
1. A process for the preparation of nd of Formula-II comprising the steps of: a) enzymatic enantioselective amidation of compound of Formula-III in presence of suitable enzyme to get amide compound of Formula-IV wherein R2 is C1-C5 alkyl or aryl or arylalkyl group; b) transesterification of compound of Formula-IV into compound of Formula-V wherein R3 is C1-C5 alkyl or aryl or arylalkyl group with proviso that R3 is different than R2 of Formula-IV; c) protecting the hydroxy group with suitable hydroxy ting group to get compound of Formula-VI n X is a suitable protecting group; d) converting the compound of Formula-VI into compound of Formula-VII; and e) converting compound of Formula-VII into compound of a-II AH26(11490917_1):RTK wherein R1 is carboxyl protecting group and X is defined above.
2. The process according to claim 1, wherein the enzyme is a hydrolase.
3. The process according to claim 2, wherein the hydrolase is lipase, esterase or protease.
4. The process according to claim 3, n lipase is Candida Antartica lipase.
5. The process according to claim 4, wherein lipase is Candida Antartica lipase B.
6. The process according to any one of the preceding claims, wherein R3 is arylalkyl group in compound of a-V.
7. The s according to any one of the preceding claims, wherein transesterification of the compound of Formula-IV is carried out in presence of st.
8. The process according to claim 7, wherein catalyst is ed from tetramethyl orthotitanate, tetraethyl itanate, tetrapropyl orthotitanate, tetraisopropyl itanate, tetrabutyl orthotitanate or tetrabenzyl orthotitanate.
9. The process according to any one of the preceding claims, wherein compound of Formula- VI is converted into compound of Formula-VII by catalytic enation.
10. The process according to any one of the preceding claims, wherein R1 is C1-C5 alkyl group in compound of Formula-II.
11. A s for the preparation of amide compound of Formula-IV comprising: enzymatic enantioselective amidation of compound of Formula-III in presence of suitable enzyme and an alcohol solvent wherein R2 is C1-C5 alkyl or aryl or arylalkyl group. AH26(11490917_1):RTK
12. A process for the preparation of a compound of Formula-II, Formula-IV, Formula-V, Formula-VI or Formula-VII, said process being substantially as hereinbefore described with nce to any of the examples.
13. The process according to any one of claims 1 to 10 or 12, wherein nd of Formula- II, Formula-IV, Formula-V, Formula-VI or Formula-VII is further converted into a HMG-CoA ase inhibitor.
14. The process according to claim 11, wherein compound of Formula-IV is further converted into a HMG-CoA reductase inhibitor.
15. The s according to claim 13 or claim 14, wherein the HMG-CoA reductase inhibitor is Rosuvastatin or Pitavastatin.
16. A compound of Formula-II, Formula-V, Formula-VI or Formula-VII, when prepared by a s according to any one of claims 1 to 10 or 12.
17. A compound of Formula IV, when prepared by a process according to claim 11 or claim
18. A compound of Formula-V wherein R3 is an arylalkyl group.
19. A compound of Formula-VI wherein X is a y protecting group, and R3 is an arylalkyl group.
20. A compound of Formula-VI AH26(11490917_1):RTK wherein X is a y protecting group selected from an alkyl, aryl, arylalkyl, trialkylsilyl or diarylalkylsilyl group, and R3 is a C1-C5 alkyl or aryl or arylalkyl group.
21. A compound of Formula-VII wherein X is a hydroxy protecting group.
22. A process for the preparation of a HMG-CoA reductase inhibitor, the process comprising the conversion of a compound of any one of claims 16 to 21 into a HMG-CoA reductase inhibitor.
23. The process according to claim 22, wherein the HMG-CoA reductase inhibitor is Rosuvastatin or Pitavastatin.
24. A HMG-CoA reductase inhibitor, when prepared by a s according to any one of claims 13 to 15 or 22 to 23. Mylan Laboratories Ltd By the Attorneys for the ant SPRUSON & ON Per: AH26(11490917_1):RTK
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4102/CHE/2011 | 2011-11-28 | ||
IN4102CH2011 | 2011-11-28 | ||
PCT/IN2012/000770 WO2013080219A2 (en) | 2011-11-28 | 2012-11-26 | NOVEL PROCESS FOR THE PREPARATION OF INTERMEDIATES OF HMG-CoA REDUCTASE INHIBITORS |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ625522A NZ625522A (en) | 2016-08-26 |
NZ625522B2 true NZ625522B2 (en) | 2016-11-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012345473B2 (en) | Process for producing chiral statin side chain intermediates employing candida|antarctica lipase B | |
US9399785B2 (en) | Lov-D acyltransferase mediated acylation | |
CA2713009C (en) | ((2s,4r)-4,6-dihydroxytetrahydro-2h-pyran-2-yl)methyl carboxylate and process for the production thereof | |
US7126003B2 (en) | Method for producing 2-azetidinone derivative | |
US20110269962A1 (en) | Process for preparing statins | |
NZ625522B2 (en) | Novel process for the preparation of intermediates of hmg-coa reductase inhibitors | |
JP3819082B2 (en) | Optically active 3-N-substituted aminoisobutyric acids and salts thereof and process for producing them | |
JPS62272983A (en) | Production of l-(-)-carnitine chloride starting from 3, 4-epoxybutyric ester | |
US6573392B1 (en) | Process for manufacturing simvastatin and the novel intermediates | |
US5973214A (en) | Method for producing an optically active 2-alkanol | |
KR20070076549A (en) | Processes for the preparations of optically active cyclopentenones and cyclopentenones prepared therefrom | |
EP0239122A2 (en) | Process for the enzymatic resolution of racemic 2-amino-1-alkanols | |
JP4476963B2 (en) | Optically active 3-N-substituted aminoisobutyric acids and salts thereof and process for producing them | |
JP4392812B2 (en) | Novel optically active 4-amino-2-methylbutyric acid derivative and method for producing the same | |
JP5092465B2 (en) | Stereoselective esterification of pipecolic acid | |
KR100650546B1 (en) | The method of preparing optically active trans-1-ramino-2-indanol and their esters by enzymatic method | |
KR100379939B1 (en) | Process for preparing [(3R,5R)/(3R,5S)]-3,5-dihydroxyhexanoic acid ester derivatives | |
JP2689211B2 (en) | Process for producing optically active 3-hydroxytetradecanoic acid ester | |
WO2004092113A1 (en) | Optically active 2-allylcarboxylic acid derivative and process for producing the same | |
JPH04299987A (en) | Production of optically active indole hydroxy acids | |
KR20040092790A (en) | Method of Preparing Statins Intermediates | |
WO2004039998A1 (en) | Method for the preparation of chiral hydroxy esters by enzyme/metal multi-catalysis | |
KR20040019540A (en) | A highly efficient synthetic process for the preparation of simvastatin and new intermediates therefor | |
JP2013110980A (en) | Method of manufacturing optically active succinimide derivative |